Roth Capital Analysts Give Lorus Therapeutics (APTO) a $6.00 Price Target

Lorus Therapeutics (NASDAQ:APTO) (TSE:APS) has been assigned a $6.00 target price by equities research analysts at Roth Capital in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective indicates a potential upside of 67.13% from the company’s current price.

APTO has been the subject of several other research reports. HC Wainwright set a $6.00 price target on shares of Lorus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, March 28th. Zacks Investment Research raised shares of Lorus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Finally, ValuEngine cut shares of Lorus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $5.63.

How to Become a New Pot Stock Millionaire

Shares of APTO traded up $0.30 during mid-day trading on Monday, hitting $3.59. The company’s stock had a trading volume of 771,854 shares, compared to its average volume of 422,159. Lorus Therapeutics has a 52-week low of $0.78 and a 52-week high of $3.97. The stock has a market capitalization of $101.01, a PE ratio of -6.90 and a beta of 2.32.

An institutional investor recently raised its position in Lorus Therapeutics stock. Acadian Asset Management LLC boosted its position in shares of Lorus Therapeutics, Inc. (NASDAQ:APTO) (TSE:APS) by 316.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the period. Acadian Asset Management LLC owned 0.17% of Lorus Therapeutics worth $100,000 as of its most recent filing with the Securities & Exchange Commission. 1.17% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at

Lorus Therapeutics Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Receive News & Ratings for Lorus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lorus Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply